Skip to content
PreclinicalResearch compound

YK‑11 (Myostatin Inhibitor SARM)

Experimental steroid-like SARM compound studied only in cells and rats, not proven in humans; may strain the liver.

Available at

The links above are labelled third-party affiliate links. MolekulaX does not sell and does not verify product quality.

YK-11 (Myostatin Inhibitor SARM) vial

DETAILED OVERVIEW

What is YK-11 (Myostatin Inhibitor SARM)?

YK-11 is an experimental compound classed as a SARM: a substance that binds to the same receptors as testosterone. Unlike the usual SARMs, its structure resembles a steroid. It has never been approved as a medicine, it is sold on the black market as a research chemical, and it is banned in competitive sport all year round.

In cell experiments it switched on the testosterone receptor and at the same time raised the level of a protein that blocks myostatin, the body's natural brake on muscle growth. It has not been tested in humans, only in the lab and in rats, and a later lab study questioned whether the effect is large enough. Because of its steroid-like structure, a risk to the liver similar to that of steroids taken by mouth is expected, and two cases of liver damage linked to it have been described. It is expected to worsen cholesterol values and may shut down the body's own testosterone production. It must not be used by women or in pregnancy, because it can cause masculinization and harm to the fetus; together with alcohol the strain on the liver grows.

Mechanism

Steroidal SARM (5α-androstane scaffold) + myostatin pathway inhibitor (follistatin upregulation)

Clinical precedent

Phase 0 in vitro only (Kanno 2011/2013, Yatsu 2018). No Phase I/II/III in humans.

Anabolic activity

AR binding ~50% testosterone (in vitro) + myostatin block dual effect

Half-life

~6-10 h (oral, estimated)

Legal status

Never an Rx. UGL 'research chemical'. WADA-banned S1.2.

Data console

Lab data

Androgenic:AnabolicEstimated 70-100:30-50 (in vitro AR-binding affinity + myostatin block dual effect, NOT classical rat bioassay).
AR bindingSteroidal SARM, AR-binding affinity ~50% of testosterone…
Active half-life~6-10 h
Detection windowUrinary: 3-5 weeks YK-11 metabolites by LC-MS/MS (WADA-accredited, target since 2018).
AromatizationNO – Δ4,9-triene configuration blocks CYP19 substrate binding. E2 does not rise.
HepatotoxicityHigh expected – 17α-methoxycarbonyl-substituted steroid-like scaffold, profile similar to 17α-methyl AAS. Solomon 2019 PMID 31077635 SARM-DILI review documented 2 YK-associated hepatocellular injury cases. TUDCA + milk-thistle + monthly ALT/AST MANDATORY.

Safety

Side effects, stop signs, contraindications

Side effects · 7

  • Hepatotoxicity (liver injury): the 17alpha-methoxycarbonyl steroidal scaffold gives a profile similar to 17alpha-alkylated oral AAS, with ALT/AST elevation and documented SARM-associated drug-induced liver injury (DILI) cases.
  • HPTA suppression: suppression of endogenous testosterone production (reduced LH/FSH), which can cause lowered libido, fatigue and post-cycle hypogonadism, requiring PCT.
  • Adverse lipid profile: marked drop in HDL (good cholesterol), typical of oral androgenic compounds, increasing cardiovascular risk.
  • Androgenic side effects: per anecdotal reports, acne, increased oiliness and possible hair loss in androgen-sensitive individuals (due to AR-agonist activity).
  • Neuropsychiatric effects: anecdotal user reports of aggression, irritability, insomnia and libido fluctuations.
  • No water retention / dry effect: it does not aromatize (Delta-4,9-triene configuration), so there is no estrogen-mediated water retention, though the dryness may anecdotally cause joint discomfort.
  • Adulteration / contamination risk: on the gray market it is often substituted with or contaminated by methylstenbolone (a cheaper 17alpha-methyl prohormone), causing different and unpredictable toxicity. An HPLC-tested source is mandatory.

Contraindications · 7

  • Pregnancy, breastfeeding and women in general: due to AR-agonist activity, risk of potentially irreversible virilization (voice deepening, hirsutism) and fetal harm; strongly contraindicated in women of childbearing age.
  • Pre-existing liver dysfunction or elevated ALT/AST: absolute contraindication given the steroidal hepatotoxicity, when baseline liver values are raised.
  • Concurrent alcohol use or other hepatotoxic agents: risk of cumulative liver injury; alcohol and other liver-burdening drugs should be avoided during the cycle.
  • Stacking with other SARMs or 17alpha-alkylated oral AAS: not advised due to cumulative hepatotoxicity and lipid toxicity.
  • Planned fatherhood / fertility concerns: HPTA suppression can temporarily impair spermatogenesis, with full recovery taking up to 3-6 months.
  • Competitive athletes: banned year-round by WADA (S1.2, other anabolic agents), detectable in urine for 3-5 weeks; will cause an anti-doping violation.
  • Pre-existing cardiovascular disease or dyslipidemia: the marked HDL drop can further worsen the lipid profile and raise cardiovascular risk.

Related Performance Compounds

Same therapeutic category

Studies

Related research and clinical findings

Telegram

Have a question about YK‑11 (Myostatin Inhibitor SARM)?

Reach out to an advisor on Telegram. Performance compounds are presented with a harm-reduction approach, based on peer-reviewed evidence.

Personalized consultation

Want a detailed conversation tailored to your data?

Fill out the prep intake form (your goals, training and health data), and the advisor prepares from it to give genuinely personalized guidance.

Fill out the form

~5–7 min · prep questionnaire · confidential · GDPR-compliant

MolekulaX Editorial Team·Source-verified · PubMed · FDA · EMA
Updated: October 14, 2026

The information here is for educational and scientific purposes only. Performance-enhancing compounds (AAS, prohormones, stimulants, doping agents) are illegal without prescription in Hungary and most of the EU, and carry serious health and legal risks. WADA bans them in competitive sport. This is NOT a usage guide, and we do not encourage any illegal use. If you do use them, medical supervision and regular bloodwork are ESSENTIAL. Severe endocrine, cardiovascular, hepatic and psychiatric side effects are possible.